Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 1

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Ocular side effects of the taxane-based chemotherapy – do only vascular disorders matter?

100%
Rzeszotarska A., Stodolska-Nowak A., Kufel-Grabowska J., Nowakowski B., Kocięcki J.
OncoReview
|
2019
|
vol. 9
|
issue 3
59-63
EN
Taxanes, whose mechanism of action is based on blocking the cells’ division of cells, have been commonly used in the chemotherapy process for over two decades. The indications for the use of taxanes include ovarian cancer, breast cancer, lung cancer, prostate cancer, some of gastrointestinal malignant tumors or Kaposi sarcoma. Currently, chemotherapy based on taxanes, as well as every cytostatic medicine, allows to improve survival outcomes in many patients with diagnosed malignancies, although it also involves the occurrence of adverse effects. These adverse events may be life-threatening or at least they can decline the patient’s quality of life. The main aim of this paper is to feature possible ocular side effects during taxane based chemotherapy. Physicians taking care of patients during chemotherapy based on taxanes, as well as on every other cytostatic medicine, should be aware of these probable ocular complications. An early diagnosis of ophthalmic complications caused by chemotherapy makes it possible to avoid long-lasting adverse effects.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.